Voloridge Investment Management’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-44,846
| Closed | -$679K | – | 1699 |
|
|
2022
Q3 | $679K | Sell |
44,846
-78,920
| -64% | -$917K | ﹤0.01% | 1223 |
|
|
2022
Q2 | $928K | Sell |
123,766
-110,859
| -47% | -$781K | ﹤0.01% | 1206 |
|
|
2022
Q1 | $2.13M | Sell |
234,625
-102,208
| -30% | -$788K | 0.01% | 926 |
|
|
2021
Q4 | $2.37M | Buy |
336,833
+256,005
| +317% | +$2.68M | 0.01% | 1009 |
|
|
2021
Q3 | $921K | Sell |
80,828
-63,644
| -44% | -$930K | 0.01% | 1308 |
|
|
2021
Q2 | $2.31M | Buy |
144,472
+2,740
| +2% | +$47K | 0.02% | 940 |
|
|
2021
Q1 | $2.53M | Sell |
141,732
-13,210
| -9% | -$228K | 0.02% | 737 |
|
|
2020
Q4 | $2.09M | Sell |
154,942
-50,228
| -24% | -$607K | 0.02% | 722 |
|
|
2020
Q3 | $2.42M | Buy |
205,170
+104,282
| +103% | +$1.27M | 0.02% | 657 |
|
|
2020
Q2 | $1.49M | Buy |
+100,888
| New | +$1.49M | 0.02% | 716 |
|
|
2019
Q4 | – | Sell |
-21,870
| Closed | -$420K | – | 1431 |
|
|
2019
Q3 | $420K | Buy |
21,870
+9,110
| +71% | +$209K | 0.01% | 848 |
|
|
2019
Q2 | $377K | Buy |
+12,760
| New | +$492K | 0.01% | 613 |
|
|
2017
Q3 | – | Sell |
-72,947
| Closed | -$3.83M | – | 570 |
|
|
2017
Q2 | $3.83M | Buy |
+72,947
| New | +$3.4M | 0.1% | 206 |
|
|
2017
Q1 | – | Sell |
-6,827
| Closed | -$258K | – | 739 |
|
|
2016
Q4 | $258K | Sell |
6,827
-36,180
| -84% | -$1.37M | 0.01% | 600 |
|
|
2016
Q3 | $1.62M | Buy |
+43,007
| New | +$948K | 0.04% | 165 |
|
Voloridge Investment Management's AERI Position: Q4 2022 in Review
Voloridge Investment Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 44,846 shares — an estimated $679K sold.
Voloridge Investment Management first reported a position in AERI in Q3 2016 and held it in 15 quarters. The position peaked at $3.83M in Q2 2017. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Voloridge Investment Management reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Voloridge Investment Management sold 44,846 Aerie Pharmaceuticals shares in Q4 2022, an estimated $679K.
- Voloridge Investment Management first reported a position in Aerie Pharmaceuticals in Q3 2016 and held it in 15 quarters.
- Voloridge Investment Management's Aerie Pharmaceuticals position peaked at $3.83M in Q2 2017.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Voloridge Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.